CA2117330C - Utilisation de composes psoralene pour l'inhibition de la restenose post-angioplastie - Google Patents

Utilisation de composes psoralene pour l'inhibition de la restenose post-angioplastie Download PDF

Info

Publication number: CA2117330C
Authority: CA; Canada
Prior art keywords: blood; psoralen; vitro; photopheresis; patient
Prior art date: 1991-12-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA002117330A

Other languages

English (en)

Other versions

CA2117330A1 (fr

Inventor

Emil Bisaccia

Albert S. Klainer

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-12-17

Filing date

1992-12-17

Publication date

2007-07-24

1991-12-17 Priority claimed from US07/809,590 external-priority patent/US5284869A/en

1992-12-17 Application filed by Individual filed Critical Individual

1993-06-24 Publication of CA2117330A1 publication Critical patent/CA2117330A1/fr

2007-07-24 Application granted granted Critical

2007-07-24 Publication of CA2117330C publication Critical patent/CA2117330C/fr

2012-12-17 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

208000037803 restenosis Diseases 0.000 title claims abstract description 24
ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical class C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 title claims description 27
238000002399 angioplasty Methods 0.000 title claims description 16
239000008280 blood Substances 0.000 claims abstract description 32
210000004369 blood Anatomy 0.000 claims abstract description 32
238000000034 method Methods 0.000 claims abstract description 24
238000000338 in vitro Methods 0.000 claims abstract description 19
SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 claims abstract description 13
-1 ultraviolet light Chemical class 0.000 claims abstract description 13
BUNGCZLFHHXKBX-UHFFFAOYSA-N 8-methoxypsoralen Natural products C1=CC(=O)OC2=C1C=C1CCOC1=C2OC BUNGCZLFHHXKBX-UHFFFAOYSA-N 0.000 claims abstract description 11
QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 claims abstract description 11
229960004469 methoxsalen Drugs 0.000 claims abstract description 11
230000005670 electromagnetic radiation Effects 0.000 claims abstract description 8
VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 claims description 15
BGEBZHIAGXMEMV-UHFFFAOYSA-N 5-methoxypsoralen Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC BGEBZHIAGXMEMV-UHFFFAOYSA-N 0.000 claims description 4
230000037396 body weight Effects 0.000 claims description 3
230000004044 response Effects 0.000 claims description 3
TUTMEHZVWWQNMW-UHFFFAOYSA-N 5-methylfuro[3,2-g]chromen-7-one Chemical compound C1=C2OC=CC2=CC2=C1OC(=O)C=C2C TUTMEHZVWWQNMW-UHFFFAOYSA-N 0.000 claims description 2
229960002045 bergapten Drugs 0.000 claims description 2
KGZDKFWCIPZMRK-UHFFFAOYSA-N bergapten Natural products COC1C2=C(Cc3ccoc13)C=CC(=O)O2 KGZDKFWCIPZMRK-UHFFFAOYSA-N 0.000 claims description 2
230000002401 inhibitory effect Effects 0.000 claims description 2
230000005764 inhibitory process Effects 0.000 claims description 2
239000000203 mixture Substances 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
229960000850 trioxysalen Drugs 0.000 claims description 2
238000011282 treatment Methods 0.000 abstract description 25
150000001875 compounds Chemical class 0.000 abstract description 24
238000001727 in vivo Methods 0.000 abstract description 9
230000003213 activating effect Effects 0.000 abstract description 4
238000007887 coronary angioplasty Methods 0.000 abstract description 4
230000037338 UVA radiation Effects 0.000 description 3
206010003210 Arteriosclerosis Diseases 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
238000013459 approach Methods 0.000 description 2
208000011775 arteriosclerosis disease Diseases 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
208000035049 Blood-Borne Infections Diseases 0.000 description 1
238000009193 PUVA therapy Methods 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000028993 immune response Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000001678 irradiating effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA002117330A 1991-12-17 1992-12-17 Utilisation de composes psoralene pour l'inhibition de la restenose post-angioplastie Expired - Fee Related CA2117330C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US07/809,590		1991-12-17
US07/809,590 US5284869A (en)	1991-12-17	1991-12-17	Photophoresis methods for treating atherosclerosis and for preventing restenosis following angioplasty
PCT/US1992/010982 WO1993011657A2 (fr)	1991-12-17	1992-12-17	Utilisation de composes de psoralen afin d'empecher la restenose suite a une angioplastie

Publications (2)

Publication Number	Publication Date
CA2117330A1 CA2117330A1 (fr)	1993-06-24
CA2117330C true CA2117330C (fr)	2007-07-24

Family

ID=38325166

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002117330A Expired - Fee Related CA2117330C (fr)	1991-12-17	1992-12-17	Utilisation de composes psoralene pour l'inhibition de la restenose post-angioplastie

Country Status (1)

Country	Link
CA (1)	CA2117330C (fr)

1992
- 1992-12-17 CA CA002117330A patent/CA2117330C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2117330A1 (fr)	1993-06-24

Legal Events

Date	Code	Title	Description
1999-12-07	EEER	Examination request
2009-12-17	MKLA	Lapsed

Publication	Publication Date	Title
US5426116A (en)	1995-06-20	Photophoresis methods for treating atherosclerosis and for preventing restenosis following angioplasty
DE69230285T2 (de)	2000-07-13	Methode zur verhinderung von restenosierung nach rekanalisierung von körpergefässen
US5514707A (en)	1996-05-07	Inhibition of smooth muscle cell proliferation by 8-methoxypsoralen photoactivated by visible light
AU670820B2 (en)	1996-08-01	Method for treating cardiovascular disease through adjunctive photodynamic therapy
Gatzemeier et al.	1995	Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer
March et al.	1993	8-Methoxypsoralen and longwave ultraviolet irradiation are a novel antiproliferative combination for vascular smooth muscle.
CA2117330C (fr)	2007-07-24	Utilisation de composes psoralene pour l'inhibition de la restenose post-angioplastie
AU753208B2 (en)	2002-10-10	The use of psoralen compounds to inhibit restenosis following angioplasty
US5219882A (en)	1993-06-15	Treatment methods for lymes disease and associated debilitating conditions
Benstead et al.	1990	The effect of combined modality treatment with ionising radiation and TPPS-mediated photodynamic therapy on murine tail skin
US4939167A (en)	1990-07-03	Use of 5-methoxypsoralen and other furocoumarins as jet lag suppressants
Sumpio et al.	1994	Inhibition of smooth muscle cell proliferation by visible light-activated psoralen.
EP0528515A2 (fr)	1993-02-24	Inhibiteurs de réductase de HMG-CoA dans la prévention de la resténose après angioplastic coronaire
EP1166784A1 (fr)	2002-01-02	Inhibiteur de reconstriction vasculaire apres une angioplastie
Asahara et al.	1993	Photodynamic therapy for the prevention of restenosis after angioplasty
Gambichler	1999	Vitiligo: Phototherapeutic options
Lavery et al.	1980	Puvatherapy for Psoriasis and Other Skin Diseases—An Initial Report
EP1349547A2 (fr)	2003-10-08	Utilisation d'acide 5-aminolevulinique pour assurer la prophylaxie de la restenose
Pfeiffer	1994	PDT Inhibits Precursor to Restenosis in Animals